Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classificação em ações #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Preço da ação
$0.25974701
Última sincronização: 2025-01-06
Valor de mercado
$2.04M
Variação (1 dia)
0.74%
Variação (1 ano)
0.00%
País
FR
Negociar Acticor Biotech SAS (ALACT)

Categoria

Healthcare
Lucros da Acticor Biotech SAS (ALACT)
Lucros em Jun 2024 TTM: $-12.93M
De acordo com os últimos relatórios financeiros da Acticor Biotech SAS, os ganhos atuais da empresa são de $-12.93M. Em 2022, a empresa teve ganhos de $-19.33M, uma diminuição em relação a aos ganhos de 2021, que foram de $-16.54M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Acticor Biotech SAS de 2010 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -40,906.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,190.08%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 30,968.98%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 23,780.79%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH